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Introduction
Frailty is an important concept in geriatric medicine and under-
standing its aetiology has become a fundamental aspiration of
many researchers in the aging field [1]. Chronic inflammation may
play a role in the pathophysiology of frailty [2, 3]. In older people,
higher circulating levels of C-reactive protein (CRP) and inter-
leukin-6 (IL-6) are inversely correlated with poor physical per-
formance, and muscle weakness [4] and higher circulating levels
of IL-6 predict the onset of disability [5]. Plasma levels of tumour
necrosis factor- (TNF-) are strongly associated with death in
community-dwelling subjects aged 72–92 years [6] and in cente-
narians [7].
Older people defined as frail by operational criteria defined
by Fried et al. [8] exhibit evidence of increased inflammation,
with higher levels of CRP [9] and IL-6 [10]. Fried’s model has
been praised for clinical reproducibility and coherency [11] and
has been validated against adverse outcome in large population
studies [8, 12]. However, it is based on physical parameters,
whereas frailty is, arguably, a complex, multi-dimensional con-
cept [13, 14]. Inflammation in Fried frail subjects may be related
primarily to sarcopenia. In the study by Ferrucci et al. [5], most
of the relationship between IL-6 and disability was accounted
for by the detrimental effect on muscle strength. Furthermore,
CRP, IL-6 and TNF- receptor-2 levels are negatively correlated
with rate of skeletal muscle protein synthesis [15], supporting
the idea that low-grade inflammation is implicated in sarcopenia
development [16].
Defining frailty is an area of ongoing debate [17] and application
of different frailty criteria can give heterogeneous results in clinical
practice [18]. The aim of the present study was to investigate
inflammation in older patients according to varied frailty criteria.
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Abstract
Inflammation in patients defined as frail by Fried’s phenotypic definition may be related to sarcopenia. This study aimed to investigate
inflammation in older patients across different frailty criteria. Frailty status was determined in 110 patients aged over 75 years (mean
83.9 years) according to function (dependent, intermediate, independent); Fried (three or more items of exhaustion, weight loss, slow
walking speed, low handgrip strength, low physical activity) and Frailty Index (a measure of accumulated deficits). With increasing
patient frailty as defined by function and by Fried phenotype, tumour necrosis factor- (TNF-), interleukin-6 (IL-6) and C-reactive pro-
tein (CRP) increased significantly. Albumin was lowest in the frailest subjects by each definition. The greatest differences were seen
between intermediate and dependent groups and between the pre-frail and frail. Adjustment for multiple covariates (age, sex, BMI cat-
egory, smoking status, number of co-morbidities and number of prescribed medications) did not account for any of the observed dif-
ferences in levels of inflammatory markers. The Frailty Index correlated significantly with log-transformed CRP (r  0.221, P  0.05),
log-transformed IL-6 (r  0.369, P  0.01), TNF- (r  0.379, P  0.01) and inversely with albumin (r  – 0.545, P  0.01). This
study provides further evidence linking inflammation and frailty in older people, an association that seems consistent across different
frailty measures.
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Materials and methods
Thirty institutionalized patients were recruited from Continuing Care wards
on four different hospital sites in Cardiff, South Wales. These inpatients
were dependent for activities of daily living, many were cognitively
impaired and all met United Kingdom National Health Service Continuing
Care criteria for ongoing nursing and medical needs [19]. Forty commu-
nity-dwelling patients with a history of falls referred to Day Hospital for
rehabilitation and 40 independent age-matched controls recruited from
poster advertisements were also studied. These patients were defined,
respectively, as dependent, intermediate and independent on a functional
frailty spectrum [20–22].
Frailty indicators were measured in all subjects by a single observer
(REH). History of weight loss, smoking status, medical diagnoses and 
drug history were self-reported by independent older people or docu-
mented from medical notes for intermediate or dependent patients. Use of
anti-inflammatory drugs (non-steroidal anti-inflammatory drugs, cyclo-
oxygenase-2 selective inhibitors and steroids) was noted. Height and
weight were measured without shoes and with light clothing, height to the
nearest 0.5 cm and weight to the nearest 0.1 kg. Height was estimated for
dependent patients who could not stand from demi-span (measured in
centimetres from the ring finger root to the sternal notch) and knee height,
as described by Hickson and Frost [23]. Body mass index (BMI) was 
calculated as weight (kg)/height (m)2 and BMI categorized as underweight
(20), recommended weight (20.0–24.9), overweight (25.0–29.9) or
obese (30.0) [24].
Participants were categorized according to Fried criteria [8] with cut-
offs for positive frailty indicators set at the lowest 20% of the independent
older group [25]: exhaustion (Energy and Vitality Score on Short-Form 36
of less than 40%), slow walking speed (6-min. walking distance of 210 m)
and low handgrip strength. Weight loss (10 pounds in preceding year)
and low physical activity (a score of 1 or 2 out of 6 on a validated physical
activity questionnaire [26]) were also Fried frailty indicators. Individuals
with three or more components were defined as frail, one or two pre-frail
and those with no positive frailty indicators as non-frail.
The Frailty Index measures frailty as a continuum rather than a
dichotomous state, an approach summarized as ‘the more things individ-
uals have wrong with them, the higher the likelihood they will be frail’
[27]. For this Frailty Index, a total of 30 variables were collected, includ-
ing self-reported data, symptoms, co-morbidities and performance-based
tests. Deficits were combined by adding them (1 for each deficit present,
0 if absent), and the Index was the total deficits as a proportion of those
counted (e.g. 6/30  0.20).
Total white blood cell (WBC) count was obtained using a Coulter counter
in the hospital-based laboratory and serum albumin and CRP measured
(Abbott AEROSET system, Abbott Laboratories, Abbott Park, IL, USA).
Plasma IL-6 and TNF- were assayed by enzyme-linked immunosorbent
assay using Quantikine® Colorimetric Kits. The optical densities were meas-
ured using a Bio-Rad Laboratories Ltd. Model 3550 Plate Reader (Hemel
Hempstead, Herts, UK) and the mean of duplicate samples calculated.
The study was approved by the Local Research Ethics Committee.
Written-informed consent was obtained from participants or, for patients
who lacked capacity to give fully informed consent, assent was obtained
from next of kin.
Data were analyzed using Stata 10.1 for UNIX. For normally distributed
variables data were reported as mean and standard deviation and the sta-
tistical significance of differences across degrees of frailty was examined
using analysis of variance. Variables with a skewed distribution (CRP and IL-6)
were expressed as median, 25th and 75th percentiles. Log-transformed
CRP values were roughly normally distributed and so were tested across
frailty groups using analysis of variance. A significant proportion of par-
ticipants had zero detectable IL-6 level and a log transformation was not
possible in those cases. Therefore, we tested the proportion of cases with
non-zero IL-6 across each group using logistic regression as well as the
log-transformed IL-6 values in non-zero cases. Analyses were conducted
univariately and after adjustment for age, sex, BMI, smoking, number of
co-morbidities and number of prescribed medications. Correlations were
explored using Pearson correlation coefficients.
Results
One hundred 10 patients were recruited [28]. Forty-four patients
were male (40%) and all were Caucasian. No subjects showed
signs of infection or were taking antibiotic treatment. Study popu-
lation characteristics are shown in Table 1.
Prevalence of Fried frailty increased from 10% in independent
older people to 72.5% in the intermediate function, Day Hospital
group and 100% of dependent, Continuing Care patients. Eleven
Day Hospital patients (27.5%) and 14 independent older people
(35%) had 1–2 frailty indicators and were ‘pre-frail’.
The Frailty Index increased significantly with increasing func-
tional dependence: from 0.15 (standard deviation 0.08) for inde-
pendent older people to 0.33 (0.08) for Day Hospital (P  0.05)
and 0.49 (0.08) for Continuing Care patients (P  0.005).
Four patients declined venesection. Sufficient venous speci-
mens were obtained to measure WBC count in 106 patients
(96%), albumin in 91 (83%), CRP in 89 (81%), IL-6 in 106 (96%)
and TNF- in 105 subjects (95%). One patient had an extreme
CRP value of 283 mg/l and one had a high lymphocyte count sec-
ondary to known chronic lymphocytic leukaemia. These cases
were excluded, respectively, from further CRP and WBC analyses.
Table 2 shows the levels of each inflammatory marker across
frailty definitions, as well as the variation of each marker within
each frailty group. With increasing patient frailty as defined by
function (independent/intermediate/dependent) and Fried pheno-
type (non-frail/pre-frail/frail), TNF- and CRP each increased sig-
nificantly. Both the presence of IL-6 and the levels in those in
which it was detectable were higher in the frailer participants.
Albumin was lowest in the frailest subjects by each definition.
Table 3 shows estimates for the differences between groups
defined by increasing levels of frailty, both univariate and adjusted
for multiple covariates. The greatest differences were seen
between intermediate and dependent groups and between the pre-
frail and frail. Adjustment for multiple covariates (age, sex, BMI
category, smoking status, number of co-morbidities and number
of prescribed medications) did not account for any of the
observed differences in levels of inflammatory markers; many dif-
ferences were more marked after adjustment.
The Frailty Index correlated significantly with log-transformed
CRP (r  0.221, P  0.05), log-transformed IL-6 (r  0.369, 
P  0.01) and TNF- (r  0.379, P  0.01). There was a signif-
icant inverse correlation between Frailty Index and albumin 
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(r  – 0.545, P  0.01) but no correlation with WBC count (r 
0.176, P  0.072).
Discussion
In this study, we have shown significant associations between
frailty and markers of inflammation. Although frailty is defined and
measured in different ways, there is universal agreement that it is
a state of increased vulnerability to a range of adverse outcome in
later life, including death, institutionalization and worsening health
[11, 13, 29–31]. We have applied three distinct measures of
frailty: the ‘phenotypic frailty’ defined by Fried and colleagues, a
Frailty Index and a measure of frailty defined by level of depend-
ence. Our results were consistent, suggesting the association with
inflammation does not depend on the specific definition or meas-
ure of frailty applied. Although older people in the ‘dependent’
group were disabled, and frailty is distinct from disability [32], we
feel that they were also frail. There was strong face validity for
choosing long-term inpatients as the ‘frailest’ group on the func-
tional frailty spectrum. Construct validation of their frailty status is
afforded by the higher prevalence of Fried frailty and significantly
© 2009 The Authors
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Fried Function
Non-frail Pre-frail Frail Independent Intermediate Dependent
n  22 n  25 n  63 n  40 n  40 n  30
% Men 55 44 33 40 40 40
P  0.195 P  1.000
Age, years * (S.D.) 79.7 (3.7) 85.2 (4.9) 84.8 (5.6) 82.7 (5.5) 84.2 (4.9) 84.9 (6.2)
P  0.005 P  0.215
Frailty Index*, †
(S.D.)
0.10 (0.05) 0.22 (0.09) 0.41 (0.10) 0.15 (0.08) 0.33 (0.08) 0.49 (0.08)
P  0.005 P  0.005
Number of co-
morbidities† (S.D.)
2.3 (1.9) 3.2 (1.8) 3.5 (1.6) 2.6 (1.5) 4.2 (1.6) 2.6 (1.3)
P  0.018 P  0.005
Prescribed medica-
tion (S.D.)*, †
2.9 (1.9) 5.6 (2.9) 5.3 (2.6) 4.0 (2.5) 6.3 (4.2) 4.3 (2.4)
P  0.005 P  0.005
Regular anti-
inflammatory 
medication
9% 20% 13% 17.5% 12.5% 10%
P  0.524 P  0.624
Smoking current 0 0 5% 0 7.5% 0
Ex 50% 52% 37% 50% 50% 23.3%
None 50% 48% 33% 50% 42.5% 23.3%
Unknown 0 0 25% 0 0 53.3%
P  0.536 P  0.364
Obesity 9% 24% 5% 12.5% 15% 0
P  0.025 P  0.094
Table 1 Study subject characteristics
*Denotes significant differences between study groups defined by Fried frailty criteria.
†Denotes significant differences between study groups defined by function.
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higher Frailty Index score in these patients. Our results were not
affected by adjusting for age, sex, BMI, smoking, the number of
medications being taken or number of co-morbidities.
The study has important limitations. Number of participants
was small. The variables were not operationalized exactly as pro-
posed by Fried and colleagues [8], although similar modifications
have been made by others who have replicated the work [33].
Such adaptations are less of a problem for the Frailty Index
approach, which does not require the same items or the same
number of items to estimate the proportions that represent the
Index’s values [34]. In this study, a Frailty Index was constructed
from 30 variables and though 40 are recommended [27], Frailty
Indices have been constructed using as few as 20 variables [35].
As with other cross-sectional studies [9, 10], the association
between frailty and inflammation provides no insights into causal-
ity. Inflammation may be part of the driving force towards disabil-
ity. Increased levels of IL-6 have been linked to physical decline
and disability [36, 37], and the development of age-related condi-
tions such as dementia, Parkinson’s disease, atherosclerosis and
type 2 diabetes is associated with elevated levels of inflammatory
mediators [38]. Furthermore, the association of inflammation with
obesity, smoking and physical inactivity may constitute a link
between life-style factors and frailty development [39].
Alternatively, inflammation may be a compensatory response.
Some genotypes are associated with increased production of cer-
tain cytokines [40]. A direct link between such genotypes and
frailty development or mortality would support a direct patho-
genetic role of inflammatory mediators. To date, no such link has
been established and the evidence regarding polymorphisms and
longevity is conflicting [39]. One of the main functions of IL-6 is
self-limiting inflammation [41]. Thus, elevated levels of IL-6 in
frailty may be aimed at resolving an inflammatory response [42]
initially triggered by viral antigens such as cytomegalovirus [43] or
other sub-clinical disease such as asymptomatic bacteriuria [44].
Thirdly, inflammation may be an epi-phenomenon, merely a
marker of the key causal mechanism. Excessive and unopposed
oxidative stress may be the core mechanism leading to age-
associated frailty [42]. Oxidative damage accumulates with age
© 2009 The Authors
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Table 2 Inflammatory markers according to different frailty criteria
Fried Function
Non-frail Pre-frail Frail Independent Intermediate Dependent
n  22 n  25 n  63 n  40 n  40 n  30
White blood cell 
count 109/l mean
(standard deviation)
6.7 (1.3) 7.1 (1.7) 7.7 (2.4) 7.1 (2.1) 7.3 (2.0) 7.8 (2.3)
P  0.095 P  0.450
Albumin g/l mean
(standard deviation)
43.4 (5.3) 44.2 (3.5) 39.5 (5.6) 44.0 (4.5) 43.0 (3.4) 34.7 (4.7)
P  0.005 P  0.005
C-reactive protein mg/l
median (25th and 75th
percentile)
3.0 (2.0–5.0) 4.0 (2.0–6.0) 5.0 (3.0–13.0) 3.5 (2.0–5.5) 4.0 (2.0–11.0) 5.5 (2–21.5)
*P  0.013 *P  0.026
IL-6 pg/ml median
(25th and 75th 
percentile)
0 (0–1.51) 0 (0–3.99) 3.59 (0.26–10.44) 0 (0–2.81) 1.48 (0–5.94) 6.97 (2.56–38.34)
*P  0.068 *P  0.005
% With detectable IL-6 41% 44% 80% 45% 67% 81%
P  0.005 P  0.011
TNF- pg/ml mean
(standard deviation)
1.50 (0.89) 1.86 (1.23) 3.19 (2.68) 1.68 (1.12) 2.01 (1.16) 4.58 (3.30)
P  0.005 P  0.005
*P  significance of differences in log-transformed values.
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Table 3 Differences in inflammatory markers between frailty groups, with 95% confidence intervals*
Function
Intermediate versus independent Dependent versus intermediate
Effect 95% CI P-value Effect 95% CI P-value
Univariate
White blood cell count 0.19 (	0.74, 1.13) 0.683 0.47 (	0.56, 1.50) 0.378
Albumin 	1.00 (	2.94, 0.94) 0.315 	8.31 (	10.53, 	6.08) P  0.005
Log-transformed C-reactive protein 0.30 (	0.23, 0.83) 0.276 0.57 (	0.03, 1.16) 0.068
Log-transformed IL-6 0.25 (	0.58, 1.08) 0.563 1.78 (1.00, 2.57) P  0.005
Detectable IL-6† 2.44 (0.98, 6.09) 0.055 2.20 (0.68, 7.14) 0.189
TNF- 0.32 (	0.52, 1.17) 0.454 2.57 (1.62, 3.52) P  0.005
Adjusted
White blood cell count 	0.37 (	1.39, 0.66) 0.485 1.85 (0.50, 3.20) 0.009
Albumin 	1.23 (	3.41, 0.96) 0.276 	7.60 (	10.88, 	4.33) P  0.005
Log-transformed C-reactive protein 0.42 (	0.14, 0.98) 0.143 1.07 (0.24, 1.90) 0.014
Log-transformed IL-6 0.17 (	0.85, 1.19) 0.746 2.70 (1.53, 3.86) P  0.005
Detectable IL-6† 1.76 (0.58, 0.54) 0.317 13.60 (1.35, 136.93) 0.027
TNF- 0.43 (	0.39, 1.25) 0.310 3.50 (2.38, 4.62) P  0.005
Fried
Pre-frail versus non-frail Frail versus pre-frail
Effect 95% CI P-value Effect 95% CI P-value
Univariate
White blood cell count 0.47 (	0.73, 1.67) 0.443 0.61 (	0.37, 1.59) 0.225
Albumin 0.82 (	2.39, 4.02) 0.618 	4.71 (	7.33, 	2.09) P  0.005
Log-transformed C-reactive protein 0.04 (	0.67, 0.74) 0.918 0.70 (0.13, 1.27) 0.019
Log-transformed IL-6 0.83 (	0.57, 2.23) 0.249 0.50 (	0.54, 1.55) 0.349
Detectable IL-6† 1.13 (0.36, 3.62) 0.831 4.50 (1.65, 12.26) P  0.005
TNF- 0.37 (	0.85, 1.59) 0.556 1.33 (0.33, 2.32) 0.011
Adjusted
White blood cell count 0.14 (	1.26, 1.54) 0.844 0.79 (	0.26, 1.85) 0.145
Albumin 0.36 (	3.14, 3.86) 0.841 	3.18 (	5.75, 	0.60) 0.018
Log-transformed C-reactive protein 0.26 (	0.53, 1.04) 0.523 0.83 (0.24, 1.41) 0.007
Log-transformed IL-6 1.14 (	0.48, 2.77) 0.173 0.47 (	0.81,1.75) 0.473
Detectable IL-6† 1.00 (0.22, 4.53) 0.999 8.28 (2.29, 29.92) P  0.005
TNF- 0.85 (	0.44, 2.14) 0.200 1.39 (0.41, 2.36) 0.007
*Both univariate differences and differences adjusted for age, sex, BMI, smoking, number of co-morbidities and number of prescribed medications
are presented. Frailty is defined both by function (top) and by Fried frailty criteria (bottom).
†Reported effect size is the odds ratio of the presence of detectable levels of IL-6 between groups.
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causing DNA, muscle and lipid damage sufficient to impair cellu-
lar and organ function [45]. Recent evidence supports a direct
causal role for reactive oxygen species (ROS) in skeletal muscle
damage. Protein carbonylation, an indirect measure of ROS mus-
cle damage, was associated with low grip strength in the Women’s
Health and Ageing Study 1 [46].
This study provides further evidence linking inflammation and
frailty in older people, an association that seems consistent across
different frailty measures. Further studies are needed to establish
the nature of this association – whether inflammation is primarily
causal, compensatory or an epi-phenomenon. Intervention studies
modulating the production or effect of inflammatory mediators are
therefore a more distant prospect.
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